NDC 50242-260

Phesgo

Pertuzumab, Trastuzumab, And Hyaluronidase-zzxf

Phesgo is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Genentech, Inc.. The primary component is Hyaluronidase (human Recombinant); Pertuzumab; Trastuzumab.

• Product ID: 50242-260_04be6beb-fee6-42cb-8b8d-ee7ac8da3262
• NDC: 50242-260
• Product Type: Human Prescription Drug
• Proprietary Name: Phesgo
• Generic Name: Pertuzumab, Trastuzumab, And Hyaluronidase-zzxf
• Dosage Form: Injection, Solution
• Route of Administration: SUBCUTANEOUS
• Marketing Start Date: 2020-06-29
• Marketing Category: BLA / BLA
• Application Number: BLA761170
• Labeler Name: Genentech, Inc.
• Substance Name: HYALURONIDASE (HUMAN RECOMBINANT); PERTUZUMAB; TRASTUZUMAB
• Active Ingredient Strength: 20000 U/10mL; mg/10mL; mg/10mL
• Pharm Classes: Endoglycosidase [EPC], Glycoside Hydrolases [CS], HER2/Neu/cerbB2 Antagonists [MoA], HER2/Neu/cerbB2 Antagonists [MoA], HER2/neu Receptor Antagonist [EPC], HER2/neu Receptor Antagonist [EPC]
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 50242-260-01

1 VIAL, SINGLE-DOSE in 1 CARTON (50242-260-01) > 10 mL in 1 VIAL, SINGLE-DOSE

• Marketing Start Date: 2020-06-29
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "Phesgo" or generic name "Pertuzumab, Trastuzumab, And Hyaluronidase-zzxf"

NDC	Brand Name	Generic Name
50242-245	Phesgo	pertuzumab, trastuzumab, and hyaluronidase-zzxf
50242-260	Phesgo	pertuzumab, trastuzumab, and hyaluronidase-zzxf